Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vicks Active SymptoMax Plus is a multi-ingredient pharmaceutical product formulated for the symptomatic relief of the common cold and influenza. It is a combination of three active ingredients: paracetamol (acetaminophen), guaifenesin, and phenylephrine hydrochloride. Paracetamol serves as an analgesic and antipyretic, reducing pain and fever by inhibiting prostaglandin synthesis in the central nervous system. Guaifenesin acts as an expectorant, increasing the volume and reducing the viscosity of secretions in the respiratory tract to facilitate mucus clearance. Phenylephrine hydrochloride is a sympathomimetic decongestant that functions as a selective alpha-1 adrenergic receptor agonist, causing vasoconstriction in the nasal mucosa to alleviate congestion. The product is typically developed as a powder for oral solution, intended for rapid absorption and relief of symptoms such as headache, sore throat, nasal congestion, and productive cough.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on paracetamol + guaifenesin + phenylephrine.